Monday, October 5, 2009

Oncothyreon Names ZymoGenetics' CEO To Board

Seattle-based Oncothyreon, a firm developing synthetic vaccines for treating cancer, said this morning that it has named Douglas E. Williams, the CEO of ZymoGenetics, to its board of directors. Williams has also served at Seattle Genetics, Immunex Corporation, and Amgen. He's also on the board of Array BioPharma and Aerovance.